Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Bergamo – page 105

2 770 clinical trials in Bergamo, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bergamo at a glance
2 770
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 770 trials in Bergamo

Open in trial search

Head and neck cancer

Not yet recruiting

Study on the Effects of Tepotinib and Cetuximab for Patients with Platinum-Resistant Head and Neck Cancer After Immunotherapy Relapse

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Muscular dystrophy

Not yet recruiting

Study on the Effectiveness of Deflazacort in Treating LMNA-related Congenital Muscular Dystrophy in Adults and Children

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Deflazacort
  • Sponsor:Azienda Ospedaliero Universitaria Pisana

Plasma cell myeloma+1

Not yet recruiting

Study on Melflufen and Dexamethasone for Elderly Patients with Relapsed Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Dexamethasone Sodium Phosphate
  • Sponsor:Fo.Ne.Sa. Fondazione Neoplasie Sangue Ets

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Universita' Degli Studi Di Torino

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety and Effectiveness of Fludarabine and Treosulfan for Stem Cell Transplant in Acute Myeloid Leukemia Patients Aged 40 to 65

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ciclosporin
  • Sponsor:Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Study on Alectinib for Patients with ALK+ Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Neoplasm

Not yet recruiting

Study on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione Centro Nazionale Di Adroterapia Oncologica

Non-small cell lung cancer+1

Not yet recruiting

Study of Niraparib and Dostarlimab for Patients with Advanced Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma with Specific Genetic Mutations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Universita' Degli Studi Di Torino

HIV infection

Not yet recruiting

Study on Doravirine and Raltegravir for Maintaining Viral Control in HIV Patients with Low Viral Load

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Centre De Recherches Et D'Etudes Sur La Pathologie Tropicale Et Le Sida

Colon cancer stage III+1

Not yet recruiting

Study on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gruppo Oncologico Del Nord Ovest

Rectal cancer stage III+1

Not yet recruiting

Study on Oxaliplatin and Capecitabine for Patients with Locally Advanced Rectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:ASST Grande Ospedale Metropolitano Niguarda

Duchenne muscular dystrophy+1

Not yet recruiting

Study on the Safety and Effectiveness of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Delandistrogene Moxeparvovec
  • Sponsor:Sarepta Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Bergamo

What the registry says about research in the country

01 Cardiovascular Research

Innovative trials exploring treatments for heart failure prevention and cardiovascular disease. Studies include evaluation of novel drug combinations and therapies for patients with elevated cardiovascular risks.

  • Heart Failure Prevention
  • Myocardial Infarction Treatment
  • Cardiovascular Risk Management
02 Oncology Studies

Comprehensive research focusing on various cancer types, including non-small cell lung cancer and prostate cancer. Studies evaluate innovative treatment approaches combining immunotherapy with traditional methods.

  • Lung Cancer Therapies
  • Prostate Cancer Treatment
  • Breast Cancer Research
03 Rare Diseases

Specialized trials investigating treatments for conditions like Alagille syndrome and amyotrophic lateral sclerosis. Research focuses on improving patient outcomes and quality of life.

  • Genetic Disorders
  • Neurological Conditions
  • Rare Blood Disorders
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.